Physician profile
Stephen P Stamatis
NPI 1902007222
$11,114.42
in general payments reported to CMS, 2019-2025
27 companies · $954 in 2025
The $954 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $139 · 2021: $371 · 2022: $209 · 2023: $9,053 · 2024: $186 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,691 · Travel and Lodging: $1,711 · Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,690.94 |
| Travel and Lodging | $1,711.15 |
| Food and Beverage | $791.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,228.14 | 2023-2025 | Davinci Xi, Da Vinci Surgical System |
| Astellas Pharma US INC | $451.34 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $394.62 | 2019-2023 | Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $180.71 | 2023-2025 | Gemtesa, Myfembree |
| Exeltis, USA INC. | $150.82 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $146.18 | 2023 | |
| Ethicon US, LLC | $79.77 | 2019-2025 | Stratafix, Dermabond Prineo, Vistaseal |
| Biogen, INC. | $71.43 | 2025 | Zurzuvae |
| Organon LLC | $55.81 | 2022-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $46.74 | 2021 | |
| Amag Pharmaceuticals, INC. | $39.71 | 2019-2021 | |
| Avion Pharmaceuticals | $36.68 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.40 | 2019-2021 | |
| Pfizer INC. | $34.19 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $23.39 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.66 | 2019 | |
| Millicent US INC | $19.93 | 2023 | Intrarosa |
| Duchesnay USA Incorporated | $16.21 | 2019 | |
| Evofem Biosciences, INC. | $15.47 | 2021 | |
| Mission Pharmacal Company | $15.44 | 2020 | |
| Novo Nordisk INC | $13.97 | 2019 | |
| Agile Therapeutics, INC. | $13.02 | 2023 | Twirla |
| Coopersurgical, INC. | $12.24 | 2019 | |
| Tela Bio, INC. | $11.55 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Stamatis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.